efficacy of semaglutide and tirzepatide in reducing liver fat vs vs retatrutide: the complete three-way comparison efficacy of semaglutide and tirzepatide

[] Considering better-glycosylated hemoglobin (HbA1c) reduction, greater weight loss, CV, and renal beneficial outcomes, daily or weekly dose of GLP1-A has been incorporated in recent ADA-EASD, ESC, and other guidelines as an initial drug of choice in patient-centric approach

Gan & Lee Pharmaceuticals reported on June 30, 2026 in Annals of Internal Medicine that its investigational GLP-1 receptor agonist bofanglutide, dosed once every two weeks, lowered HbA1c at least as much as weekly semaglutide in a 272-patient phase 2b trial in adults with type 2 diabetes

At the same time, the out-of-pocket maximum establishes the annual limit on total member costs, including deductibles, copays, and coinsurance

Growing global demand for GLP-1 medicines has increased interest in affordable alternatives, particularly in countries where access has been limited by the high cost of branded therapies